NCT05097482 (TriUS) is a clinical trial in Spastic Foot, sponsored by Alessio Baricich.

Who is sponsoring NCT05097482?

NCT05097482 is sponsored by Alessio Baricich.

What condition does NCT05097482 study?

NCT05097482 studies Spastic Foot, Stroke.

Is NCT05097482 still recruiting?

NCT05097482 is currently status unknown. Last updated 28 October 2021.

Last reviewed 2021-10-28 · How we verify

NCT05097482: TriUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Triceps Surae Ultrasonographic Characteristics in Hemiparetic Stroke Survivors

Status unknown Last updated 28 October 2021

What this trial tests

trial in Spastic Foot in 50 participants. Status unknown.

Timeline

14 January 2021

Primary endpoint
13 December 2021

13 December 2021

Quick facts

Lead sponsor	Alessio Baricich
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	14 January 2021
Primary completion	13 December 2021
Estimated completion	13 December 2021
Sites	1 location across Italy

Conditions studied

Spastic Foot — all drugs for Spastic Foot →
Stroke — all drugs for Stroke →

Sponsor

Alessio Baricich

Who can join

18 and older, any sex, with Spastic Foot or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate, in hemiparetic patients, changes in muscle ultrasound structure about the focal treatment of spasticity with botulinum toxin type A. For this purpose, the analysis of the mean echo intensity will be carried out on ultrasound acquisitions, identifying the possible correlations between the muscle echogenicity, the variations in the pennation angle, and the length of the fascicles. For image processing operations, ImageJ software was applied.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Triceps Surae Muscle Characteristics in Spastic Hemiparetic Stroke Survivors Treated with Botulinum Toxin Type A: Clinical Implications from Ultrasonographic Evaluation.
Battaglia M, Cosenza L, Scotti L, Bertoni M, et al · · 2021 · cited 13× · PMID 34941726 · DOI 10.3390/toxins13120889

Verify or expand the search:

Other recruiting trials for Spastic Foot

Currently open trials in the same condition.

NCT05874154 — Evaluation of Tibial Nerve Selective Neurotomy Compared to Botulinum Toxin Injections for Spastic Foot Treatment in Post · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05097482 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alessio Baricich
Last refreshed: 28 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05097482.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing